Plymouth, United States
SilkTech Biopharmaceuticals, founded in 2013, stands as a pioneering force in the intersections of Biotechnology and Health Care. Headquartered in the United States, the company specializes in developing silk-based anti-inflammatory therapies, targeting conditions like Dry Eye Disease - a chronic inflammatory ailment.
Known for being a VC-backed entity, SilkTech is notable for having multiple patented silk protein-derived formulations currently progressing through FDA Clinical Trials. This strategic focus not only highlights their commitment to innovative treatments but also underscores the growth potential within this niche segment of biopharmaceuticals.
The company's most recent financial milestone occurred on April 16, 2019, when it secured a $6.20M Series B investment from Skyview Capital. This injection of capital is a testament to investor confidence in SilkTech's scientific expertise and market potential, positioning it as a significant player to watch in biotech innovation.
